Expanded AngioSeal Supply Deal Heightens Investor Interest In Kensey Nash
This article was originally published in The Gray Sheet
Executive Summary
Kensey Nash's ability to convince investors that AngioSeal will generate sales exceeding $75 mil. over the life of a multi-year contract with St. Jude Medical helped the supplier's stock price swell by more than 11% during June